PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-2634.20%
Negative EBIT growth while Biotechnology median is 0.00%. Seth Klarman would check if external or internal factors caused the decline.
-468.26%
Negative operating income growth while Biotechnology median is 0.00%. Seth Klarman would check if structural or cyclical issues are at play.
-263.73%
Negative net income growth while Biotechnology median is 0.00%. Seth Klarman would investigate factors dragging net income down.
-197.18%
Negative EPS growth while Biotechnology median is 0.00%. Seth Klarman would explore whether share dilution or profit declines are to blame.
-197.18%
Negative diluted EPS growth while Biotechnology median is 0.00%. Seth Klarman would look for the cause: weakened profitability or heavier share issuance.
22.83%
Share change of 22.83% while Biotechnology median is zero. Walter Schloss would see if the modest difference matters long-term.
22.83%
Diluted share change of 22.83% while Biotechnology median is zero. Walter Schloss might see a slight difference in equity issuance policy.
No Data
No Data available this quarter, please select a different quarter.
-36.01%
Negative OCF growth while Biotechnology median is 0.00%. Seth Klarman would ask if accounting or macro issues hamper the firm specifically.
-62.21%
Negative FCF growth while Biotechnology median is 0.00%. Seth Klarman would see if others in the industry are still generating positive expansions in free cash.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-319.11%
Negative 10Y OCF/share CAGR while Biotechnology median is 0.00%. Seth Klarman would suspect the firm is failing to keep pace with industry peers.
-319.11%
Negative 5Y OCF/share CAGR while Biotechnology median is 0.00%. Seth Klarman might see a firm-specific issue if peers still expand cash flow.
52.30%
3Y OCF/share growth > 1.5x Biotechnology median of 0.35%. Joel Greenblatt might see a recent competitive advantage translating into cash improvements.
-5305.80%
Negative 10Y net income/share CAGR vs. Biotechnology median of 19.75%. Seth Klarman might see a fundamental problem if peers maintain growth.
-5305.80%
Negative 5Y CAGR while Biotechnology median is 26.60%. Seth Klarman might see a specific weakness if peers maintain profitable expansions.
-47.53%
Negative 3Y CAGR while Biotechnology median is 21.34%. Seth Klarman might see a pressing concern if the rest of the sector is stable or growing.
-1146.88%
Negative 10Y equity/share growth while Biotechnology median is 0.00%. Seth Klarman would see a firm-specific weakness if peers still expand equity.
-1146.88%
Negative 5Y equity/share growth while Biotechnology median is 0.00%. Seth Klarman suspects firm-specific weaknesses if peers grow equity mid-term.
3.51%
3Y equity/share CAGR of 3.51% while Biotechnology median is zero. Walter Schloss sees a modest short-term advantage that could compound if momentum persists.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-100.00%
AR shrinking while Biotechnology median grows. Seth Klarman sees potential advantage unless it signals declining demand.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
9.29%
BV/share growth of 9.29% while Biotechnology is zero. Walter Schloss sees a slight lead that can expand if sustained over time.
10.32%
Debt growth of 10.32% while Biotechnology median is zero. Walter Schloss might see a modest difference that matters if interest coverage is tight.
No Data
No Data available this quarter, please select a different quarter.
402.37%
SG&A growth of 402.37% while Biotechnology median is zero. Walter Schloss sees a modest overhead increase needing revenue justification.